Brief Legal News Write-Up
Abbott Product Operations AG v. Menschlich Healthcare (OPC) Private Limited & Anr.
Date of Judgment: 15.06.2026 : Case No.: Commercial Miscellaneous Petition (L) No. 12147 of 2025 with Interim Application (L) No. 14697 of 2025 : Neutral Citation: 2026:BHC-OS:13226 : Court: High Court of Judicature at Bombay, Ordinary Original Civil Jurisdiction : Hon'ble Judge: Justice Arif S. Doctor
The Court considered a dispute concerning rectification and cancellation of a pharmaceutical trademark allegedly deceptively similar to a family of well-known registered trademarks. The case arose from allegations that the respondent obtained registration of the trademark “DUPHACHRIT” for pharmaceutical products despite the petitioner's longstanding rights in the “DUPHA” family of marks, including DUPHASTON and DUPHALAC.
The principal question before the Court was whether the registration of “DUPHACHRIT” was liable to be removed from the Register of Trade Marks on the ground that it was deceptively similar to the petitioner’s earlier registered “DUPHA” family of marks and likely to cause confusion in relation to pharmaceutical products.
After examining the material on record and the submissions of the parties, Justice Arif S. Doctor observed that “DUPHA” was the essential and distinctive source identifier of the petitioner’s family of marks and that the addition of the suffix “CHRIT” did not sufficiently distinguish the impugned mark. The Court held that “DUPHACHRIT” was deceptively similar to the petitioner’s registered marks and that the respondent’s adoption of the mark was dishonest and lacking bona fides, emphasizing that a stricter standard applies in pharmaceutical trademark disputes because confusion may adversely affect public health.
Accordingly, the Court allowed the rectification petition and directed that the trademark “DUPHACHRIT” bearing Registration No. 5027549 in Class 5 be rectified, cancelled, and removed from the Register of Trade Marks.
Disclaimer: Readers are advised not treat this as a substitute for legal advise as it is based on limited information and is intended solely for general informational purposes.
Bombay High Court Orders Cancellation of “DUPHACHRIT” Trademark, Upholds Abbott’s Rights in “DUPHA” Family of Pharmaceutical Marks
Introduction
The Bombay High Court's decision in Abbott Product Operations AG v. Menschlich Healthcare (OPC) Private Limited & Anr. is a significant judgment concerning trademark protection in the pharmaceutical sector. The Court was called upon to determine whether a later registered pharmaceutical trademark could continue to remain on the Register when it closely resembled a long-established family of trademarks used by a leading pharmaceutical company.
The judgment is important because it reiterates the strict standards applicable to pharmaceutical trademarks. Courts have consistently recognized that confusion between medicinal products is fundamentally different from confusion involving ordinary consumer goods. Mistakes in pharmaceutical products may have serious health consequences, making trademark protection in this sector a matter of public interest as much as private commercial rights.
The ruling provides valuable guidance to pharmaceutical companies, trademark owners, intellectual property practitioners, regulatory authorities, and businesses involved in branding medicinal products.
Factual and Procedural Background
The petitioner, Abbott Product Operations AG, filed a petition under Sections 47 and 57 of the Trade Marks Act, 1999 seeking rectification, cancellation, and removal of the trademark “DUPHACHRIT” from the Register of Trade Marks. The impugned trademark had been registered in Class 5 on 1 July 2021 in the name of Menschlich Healthcare (OPC) Private Limited.
The petitioner traced the origin of its rights to the year 1949 when its predecessors coined and adopted the mark “DUPHAR,” derived from the expression “Dutch Pharmaceuticals.” Over the decades, a number of trademarks containing the distinctive element “DUPHA” were adopted and registered, including DUPHAR, DUPHASTON, DUPHALAC, DUPHALAC FIBER, DUPHAPRO, DUPHABEARS, DUPHACHEWS, DUPHAACTIVE, and DUPHAPLUS. These marks collectively came to be known as the petitioner’s “DUPHA family of marks.”
The petitioner's earliest Indian registration dated back to 22 March 1951. The Court noted that products sold under the marks DUPHASTON and DUPHALAC generated substantial sales and enjoyed significant goodwill both in India and internationally. The petitioner also produced evidence of extensive promotional activities and prior enforcement actions undertaken to protect its trademark rights.
In August 2024, the petitioner became aware of the respondent’s registration of “DUPHACHRIT” and issued a cease-and-desist notice seeking voluntary cancellation of the registration. The respondent refused, asserting that the marks were phonetically dissimilar. Consequently, the petitioner instituted rectification proceedings before the Bombay High Court.
Dispute Before the Court
The principal issue before the Court was whether the trademark “DUPHACHRIT” had been wrongly entered on the Register and whether it was liable to be removed under Section 57 of the Trade Marks Act, 1999.
The petitioner argued that “DUPHA” was the dominant and essential feature of its family of marks and that the respondent had merely added the suffix “CHRIT” to create a deceptively similar mark. It was contended that consumers of average intelligence and imperfect recollection would likely associate the impugned mark with the petitioner’s well-known pharmaceutical products. The petitioner further argued that pharmaceutical trademarks are subject to a stricter standard because even a small possibility of confusion may have serious consequences.
The respondent contended that trademarks must be considered as a whole and that “CHRIT” created a distinct commercial identity. It argued that “DUPHA” was common to the pharmaceutical trade, that several third-party marks containing the same prefix existed, and that the petitioner could not claim an exclusive monopoly over the prefix. The respondent also relied upon Section 17 of the Trade Marks Act and argued that rights existed only in the composite marks and not in an isolated component thereof.
Reasoning and Analysis of the Court
The Court undertook a detailed analysis of the principles governing deceptive similarity in pharmaceutical trademarks.
The Court first noted that the petitioner was the prior registered proprietor of numerous “DUPHA” formative marks, many of which had existed for decades. It observed that “DUPHA” was not generic or descriptive and was historically derived from “Dutch Pharmaceuticals.” The Court further emphasized that the products sold under the impugned mark and the petitioner’s mark DUPHASTON contained the same active pharmaceutical ingredient, namely dydrogesterone.
The Court relied extensively upon the landmark decision of the Supreme Court in Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd., (2001) 5 SCC 73. The principles laid down in Cadila require consideration of visual, phonetic, and structural similarity, the nature of goods, the class of purchasers, and the circumstances in which products are purchased and consumed. The Court highlighted that Cadila mandates a stricter standard for pharmaceutical products because confusion may adversely affect health and life itself.
The Court also referred to Macleods Pharmaceuticals Ltd. v. Union of India, 2023 SCC OnLine Bom 408, which reaffirmed that even the slightest possibility of confusion in medicinal products warrants judicial intervention and that public interest and purity of the register remain paramount considerations.
While considering the respondent’s argument that marks must be compared as a whole, the Court observed that the dominant feature “DUPHA” immediately connected the impugned mark with the petitioner’s family of marks. The addition of the suffix “CHRIT” was insufficient to eliminate the association created by the distinctive prefix. The Court held that a consumer of average intelligence and imperfect recollection would likely perceive “DUPHACHRIT” as another member of the petitioner’s “DUPHA” family of products.
The Court also rejected the contention that prescription medicines are immune from confusion. Relying on Cadila, it noted that prescription requirements often do not prevent confusion because medicines are frequently sold over the counter, prescriptions may be difficult to read, and human error by doctors or pharmacists cannot be ruled out.
The Court further relied upon Ciba Ltd. Basle Switzerland v. M. Ramalingam and reiterated that the primary duty of the Court in rectification proceedings is to maintain the purity of the Register and protect the public from confusion. It emphasized that trademark disputes of this nature are not merely contests between rival traders but involve broader public interest considerations.
The Court found that the respondent had failed to provide any convincing explanation for adopting the term “DUPHA,” especially when it was neither descriptive nor generic. Considering the petitioner’s longstanding reputation, the Court concluded that the adoption was dishonest and intended to take advantage of the goodwill associated with the petitioner’s marks.
The Court also rejected arguments based on alleged third-party use, holding that mere entries on the Register do not establish that a mark is common to the trade. It relied upon Corn Products Refining Co. v. Shangrila Food Products Ltd., AIR 1960 SC 142 and Pidilite Industries Ltd. v. Riya Chemy, 2022 SCC OnLine Bom 5077, to hold that the burden of proving extensive third-party use lies on the party asserting it and that a registrant cannot simultaneously claim registration while arguing that the essential feature of the mark is common to the trade.
Final Decision of the Court
The Bombay High Court allowed the rectification petition filed under Section 57 of the Trade Marks Act, 1999.
The Court directed that the entry relating to the trademark “DUPHACHRIT” bearing Registration No. 5027549 in Class 5 be rectified, cancelled, and removed from the Register of Trade Marks. The Court made no order as to costs. The connected interim application was disposed of as a consequence of the final decision.
Point of Law Settled
The judgment reaffirms that in pharmaceutical trademark disputes, courts must apply a stricter standard when assessing deceptive similarity because confusion may affect public health and safety. Even minor variations in suffixes or additional elements may not be sufficient to distinguish a mark where the dominant and source-identifying feature remains substantially identical.
The decision also reinforces the legal recognition of a “family of marks” doctrine in trademark law. Where a trader has established extensive use and reputation in a distinctive series of marks sharing a common element, a later entrant may not adopt that essential feature merely by adding a different suffix or variation.
Further, the judgment emphasizes that the purity of the Register remains a central consideration in rectification proceedings and that dishonest adoption of a well-known trademark element will not be permitted to remain on the Register.
Case Details:
Title of the Case: Abbott Product Operations AG Vs. Menschlich Healthcare (OPC) Private Limited & Anr.
Date of Judgment/Order: 15.06.2026
Case Number: Commercial Miscellaneous Petition (L) No. 12147 of 2025; Interim Application (L) No. 14697 of 2025
Neutral Citation: 2026:BHC-OS:13226
Name of Court: High Court of Judicature at Bombay, Ordinary Original Civil Jurisdiction
Name of Hon'ble Judge: Justice Arif S. Doctor
Written By: Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi
Disclaimer: Images used herein do not reflect actual images used in Judgement and that the same are for illustrative purpose only. Readers are advised not to treat this as substitute for legal advice as it may contain errors in perception, interpretation, and presentation.
Suggested SEO Titles:
Bombay High Court Cancels DUPHACHRIT Trademark in Abbott’s DUPHA Family Marks Case
Abbott Wins Trademark Rectification Against DUPHACHRIT Registration
Bombay HC Applies Strict Standard to Pharmaceutical Trademark Dispute
DUPHACHRIT Removed from Trademark Register: Key Bombay High Court Judgment
Family of Marks Doctrine Upheld in Pharmaceutical Trademark Case
Bombay High Court Protects Abbott’s DUPHA Family of Trademarks
Pharmaceutical Trademark Confusion and Public Interest: Important Bombay HC Ruling
Trademark Rectification Under Section 57: Analysis of Abbott v Menschlich Healthcare
Bombay HC Reaffirms Cadila Principles in Pharmaceutical Trademark Disputes
Dishonest Adoption of Pharmaceutical Trademark Leads to Cancellation of Registration
Public Interest and Purity of Register: Bombay HC Trademark Judgment Explained
DUPHASTON and DUPHALAC Reputation Protected by Bombay High Court
Suggested SEO Tags:
Trademark Rectification, Pharmaceutical Trademark, Trade Marks Act 1999, Section 57 Trade Marks Act, Abbott Product Operations AG, Menschlich Healthcare, DUPHACHRIT, DUPHASTON, DUPHALAC, Family of Marks, Deceptive Similarity, Pharmaceutical Branding, Bombay High Court, Trademark Cancellation, Trademark Registration, Intellectual Property Law, Cadila Health Care Case, Macleods Pharmaceuticals Case, Trademark Litigation India, Public Interest in Trademark Law, Purity of Register, Trademark Dispute, Pharmaceutical Industry, Brand Protection, Well Known Trademark, Trademark Jurisprudence, IP Litigation, Trade Mark Rectification Proceedings, AdvocateAjayAmitabhSuman, IPAdjutor
Headnote of the Judgment:
Abbott Product Operations AG v. Menschlich Healthcare (OPC) Private Limited & Anr., Bombay High Court, Commercial Miscellaneous Petition (L) No. 12147 of 2025, Neutral Citation 2026:BHC-OS:13226, decided on 15.06.2026. The petitioner sought rectification and cancellation of the trademark “DUPHACHRIT” under Section 57 of the Trade Marks Act, 1999, alleging deceptive similarity with its long-established “DUPHA” family of pharmaceutical marks. The Bombay High Court held that “DUPHACHRIT” was deceptively similar to the petitioner’s registered marks, that the adoption of the mark was dishonest, and that a stricter standard applies in pharmaceutical trademark disputes due to public health concerns. The Court allowed the petition and directed cancellation and removal of the impugned trademark from the Register of Trade Marks.
Infographic Thumbnail Prompt:
Create a professional legal news YouTube thumbnail featuring the Bombay High Court building, pharmaceutical branding elements, trademark symbols (™), medicine strips, prescription drug packaging, and legal documents. Prominently display the text: “BOMBAY HC CANCELS DUPHACHRIT”, “ABBOTT WINS TRADEMARK CASE”, and “DUPHA FAMILY OF MARKS PROTECTED”. Include visual comparison of “DUPHASTON”, “DUPHALAC”, and “DUPHACHRIT” with highlighted common prefix “DUPHA”. Show scales of justice, a trademark registration certificate being cancelled, and a red stamp reading “REMOVED FROM REGISTER”. Use a professional legal and pharmaceutical theme with blue, white, red, and gold accents. Emphasize public health concerns, deceptive similarity, trademark rectification, and protection of well-known pharmaceutical brands. Use attached image as Image of lawyer in lawyers dress at left bottom corner which should cover 20 % of entire image area.
No comments:
Post a Comment